|
Volumn 4, Issue 6, 2000, Pages 347-351
|
13th Annual Congress of the European Society of Intensive Care Medicine, Rome, Italy, 1-4 October 2000
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ACTIVATED PROTEIN C;
BLOOD SUBSTITUTE;
DROTRECOGIN;
RECOMBINANT ANTITHROMBIN III;
UNCLASSIFIED DRUG;
CLINICAL TRIAL;
CONFERENCE PAPER;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DOUBLE BLIND PROCEDURE;
GENETIC SUSCEPTIBILITY;
GENETIC VARIABILITY;
HUMAN;
HUMAN CELL;
HUMAN TISSUE;
INFECTION RISK;
INTENSIVE CARE;
MULTICENTER STUDY;
PATHOGENESIS;
PHASE 3 CLINICAL TRIAL;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL;
RESPIRATORY FAILURE;
SCORING SYSTEM;
SEPSIS;
|
EID: 0033638851
PISSN: 13648535
EISSN: None
Source Type: Journal
DOI: 10.1186/cc719 Document Type: Conference Paper |
Times cited : (5)
|
References (9)
|